Cat. No.: HY-184448

CIB-Q22

Name: CIB-Q22
Brand: MedChemExpress
SKU: HY-184448
Price: 130.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

CIB-Q22 is a potent pyruvate carboxylase (PC) inhibitor with an IC₅₀ of 1.74 nM. CIB-Q22 suppresses hepatocellular carcinoma (HCC) cell proliferation, migration, and invasion. CIB-Q22 induces apoptosis and ferroptosis, promotes mitochondrial oxidative stress and dysfunction, inhibits glycolysis and anaplerotic flux, and reverses epithelial-mesenchymal transition (EMT). CIB-Q22 can be used for the study of hepatocellular carcinoma.

For research use only. We do not sell to patients.

Purity : 99.03%
CAS No.: 2963747-43-3
Formula: C₁₈H₂₂FNO₄
Molecular Weight:335.37

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

CIB-Q22 Chemical Structure

CAS No.: 2963747-43-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

Bax

Bcl-2

Caspase 3

GPX4

All Caspase Isoforms :

All Bcl-2 Family Isoforms :

All PARP Isoforms :

All Glutathione Peroxidase Isoforms :

GPX1
GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC50	213.5 nM	Exhibits potent cytotoxicity against A549 cells for 48 h. Exhibits potent cytotoxicity against A549 cells for 48 h.	42286802
Huh-7	IC50	78.86 nM	Exhibits potent cytotoxicity against Huh-7 cells for 48 h. Exhibits potent cytotoxicity against Huh-7 cells for 48 h.	42286802
MHCC97L	IC50	153.3 nM	Exhibits potent cytotoxicity against MHCC97L cells for 48h. Exhibits potent cytotoxicity against MHCC97L cells for 48h.	42286802
HCCLM3	IC50	25.18 nM	Exhibits potent cytotoxicity against HCCLM3 cells for 48 h. Exhibits potent cytotoxicity against HCCLM3 cells for 48 h.	42286802

In Vitro

CIB-Q22 (48 h) exhibits potent cytotoxicity against HCCLM3, Huh-7, MHCC97L, and A549 cells, with IC₅₀ values of 25.18 nM, 78.86 nM, 153.3 nM, and 213.5 nM, respectively^[1].
CIB-Q22 (48 h) shows minimal cytotoxicity against SK-Hep-1 cells, which express low levels of PC, as well as against normal RPE-1 cells^[1].
CIB-Q22 shows no significant cardiotoxicity in a hERG potassium channel inhibition assay compared to the positive control Terfenadine (HY-B1193)^[1].
CIB-Q22 (10-40 nM; 21 days) suppresses the proliferative capacity of HCCLM3 cells ^[1].
CIB-Q22 (2-10 nM; 24 h) decreases the migration and invasion of HCCLM3 cells, upregulates E-cadherin, and downregulates N-cadherin and fibronectin^[1].
CIB-Q22 (40-160 nM; 48 h) induces apoptosis in HCCLM3 cells^[1].
CIB-Q22 (50-1600 nM; 52 °C) stabilizes PC thermal stability in HCCLM3 cells in a dose-dependent manner^[1].
CIB-Q22 (40-160 nM; 0-48 h) activates Caspase-3 and induces PARP cleavage in HCCLM3 cells in time- and concentration-dependent manners^[1].
CIB-Q22 (40-160 nM; 48 h) induces mitochondrial dysfunction in HCCLM3 cells^[1].
CIB-Q22 (40-160 nM; 48 h) increases the levels of lipid peroxidation in HCCLM3 cells^[1].
CIB-Q22 (40-160 nM; 48 h) induces ferroptosis in HCC cells in a PC-dependent manner^[1].
CIB-Q22 (40 nM; 1-6 h) induces a significant increase in intracellular ROS production in HCCLM3 cells^[1].
CIB-Q22 (40 nM; 24 h) induces oxidative stress in HCCLM3 cells, as evidenced by reduced NADH/NAD⁺ and GSH/GSSG ratios, decreased ATP levels, and suppressed glucose consumption and lactate production^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HCCLM3 cells
Concentration:

2, 5, or 10 nM
Incubation Time:

24 h
Result:

Upregulated E-cadherin and downregulated N-cadherin and fibronectin in HCCLM3 cells.

Western Blot Analysis^[1]

Cell Line:

HCCLM3 cells
Concentration:

40, 80, or 160 nM
Incubation Time:

0, 2, 4, 12, 24 or 48 h
Result:

Activated Caspase-3 and induced PARP cleavage in a time-dependent manner (160 nM; (0, 2, 4, 12, 24 or 48 h). Activated Caspase-3 and induced PARP cleavage in a concentration-dependent manner (40, 80, or 160 nM; 48 h).

Western Blot Analysis^[1]

Cell Line:

HCCLM3 cells
Concentration:

40, 80, or 160 nM
Incubation Time:

48 h
Result:

Downregulated GPX4 and SLC7A11/xCT expression; induced ferroptosis in a PC-dependent manner.

Cell Proliferation Assay^[1]

Cell Line:

HCCLM3 cells
Concentration:

10, 20, or 40 nM
Incubation Time:

21 days
Result:

Suppressed the proliferative capacity of HCCLM3 cells in a concentration-dependent manner.

Cell Invasion Assay^[1]

Cell Line:

HCCLM3 cells
Concentration:

2, 5, or 10 nM
Incubation Time:

24 h
Result:

Decreased the number of invading HCCLM3 cells.

Apoptosis Analysis^[1]

Cell Line:

HCCLM3 cells
Concentration:

40, 80, or 160 nM
Incubation Time:

48 h
Result:

Induced apoptosis in HCCLM3 cells in a concentration-dependent manner.

Immunofluorescence^[1]

Cell Line:

HCCLM3 cells
Concentration:

40 nM
Incubation Time:

0, 1, 3, or 6 h
Result:

Induced a significant increase in intracellular ROS production.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-∞	AUC_0-t	MRT_0-t	MRT_0-∞	C₀	V_ss	CL	V_z	F
Mice^[1]	10 mg/kg	i.v.	1.21 h	0.083 h	5793.9 ng/mL	3062.96 ng·h/mL	3073.17 ng·h/mL	0.69 h	0.72 h	8129.43 ng/mL	239.02 mL/kg	337.77 mL/h/kg	599.15 mL/kg	/
Mice^[1]	25 mg/kg	p.o.	1.79 h	0.33 h	508.67 ng/mL	1060.10 ng·h/mL	1069.27 ng·h/mL	2.49 h	2.62 h	/	/	/	/	13.84 %

In Vivo

CIB-Q22 (15-50 mg/kg ; i.p.; every 2 days; 21 days) suppresses tumor growth in an orthotopic HCC mouse model (MHCC97L-luciferase cells in SCID mice) without causing significant body weight changes, exhibiting comparable antitumor efficacy but improved safety compared to Sorafenib (HY-10201) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Five-week-old male SCID mice are orthotopically injected with 50 μL of 1 × 10⁶ MHCC97L-luciferase cells into the left liver lobe ^[1]
Dosage:

15 mg/kg, 30 mg/kg, 50 mg/kg
Administration:

Intraperitoneal injection (i.p.); every 2 days; 21 days (starting 7 days after tumor implantation)
Result:

Significantly inhibited tumor growth in a dose-dependent manner. Did not cause significant body weight changes at any dose, indicating minimal systemic toxicity. H&E staining of major organs revealed no evident pathological abnormalities, suggesting favorable long-term safety. Immunohistochemical (IHC) analysis of tumor tissues showed significantly reduced GPX4 expression and increased 4-HNE level, a key marker of ferroptosis. TUNEL staining demonstrated increased apoptotic cell death within tumor tissues.

Related Protocols :

Chemical Information

CAS No. 2963747-43-3
Appearance Solid
Molecular Weight 335.37
Formula C₁₈H₂₂FNO₄
SMILES

NC1=C(F)C(CCC2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (298.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9818 mL

14.9089 mL

29.8178 mL

5 mM

0.5964 mL

2.9818 mL

5.9636 mL

10 mM

0.2982 mL

1.4909 mL

2.9818 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.45 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Qiao Z, et al. Design, Synthesis, and Evaluation of Bibenzyl Analogues against Hepatocellular Carcinoma by Targeting Pyruvate Carboxylase. J. Med. Chem. 2026 Jun 25;69(12):14333-14364. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9818 mL	14.9089 mL	29.8178 mL	74.5445 mL
	5 mM	0.5964 mL	2.9818 mL	5.9636 mL	14.9089 mL
	10 mM	0.2982 mL	1.4909 mL	2.9818 mL	7.4545 mL
	15 mM	0.1988 mL	0.9939 mL	1.9879 mL	4.9696 mL
	20 mM	0.1491 mL	0.7454 mL	1.4909 mL	3.7272 mL
	25 mM	0.1193 mL	0.5964 mL	1.1927 mL	2.9818 mL
	30 mM	0.0994 mL	0.4970 mL	0.9939 mL	2.4848 mL
	40 mM	0.0745 mL	0.3727 mL	0.7454 mL	1.8636 mL
	50 mM	0.0596 mL	0.2982 mL	0.5964 mL	1.4909 mL
	60 mM	0.0497 mL	0.2485 mL	0.4970 mL	1.2424 mL
	80 mM	0.0373 mL	0.1864 mL	0.3727 mL	0.9318 mL
	100 mM	0.0298 mL	0.1491 mL	0.2982 mL	0.7454 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CIB-Q22

All Caspase Isoforms

All Bcl-2 Family Isoforms

All PARP Isoforms

All Glutathione Peroxidase Isoforms